The Botox maker’s 2026 profit forecast surpassed Wall Street’s expectations, though investors saw vulnerabilities in the company’s filler brand Juvéderm.
Source link
Abbvie Shares Fall as Wall Street Focuses on Filler Weakness
Essilorluxottica Beats Forecasts, AI Glasses and Myopia Products Drive Growth
Franco-Italian eyewear maker EssilorLuxottica reported a 15 percent rise in first-half adjusted operating profit on Tuesday, comfortably beating analysts’ expectations,…
Brazil’s Natura Sees Second-Quarter Revenue Down 9% to 10% Year on Year
The cosmetics maker said it is taking measures to restore growth in Brazil, including supply-chain adjustments and an acceleration in…
Estée Lauder Companies and Puig End M&A Talks
Discussions of a merger between the beauty giants have fallen through after reports that Charlotte Tilbury was renegotiating her contract.…